Targeting the mutant p53 secretome

Por Sehgal, Kartik, Barbie, David A.
Publicado no J Clin Invest (2021)

Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?

Por Sehgal, Kartik, Costa, Daniel B., Rangachari, Deepa
Publicado no Front Oncol (2020)

Targeting human dendritic cells in situ to improve vaccines

Por Sehgal, Kartik, Dhodapkar, Kavita M., Dhodapkar, Madhav V.
Publicado no Immunol Lett (2014)

Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors

Por Sehgal, Kartik, Patell, Rushad, Rangachari, Deepa, Costa, Daniel B.
Publicado no Transl Cancer Res (2018)

Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer?

Por Piper, Andrew J., Sehgal, Kartik, Costa, Daniel B., Rangachari, Deepa
Publicado no Transl Lung Cancer Res (2019)

Nanoparticle-mediated combinatorial targeting of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via IL-15-dependent DC crosstalk

Por Sehgal, Kartik, Ragheb, Ragy, Fahmy, Tarek M., Dhodapkar, Madhav V., Dhodapkar, Kavita M.
Publicado no J Immunol (2014)

Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR‐G719A and Other Uncommon EGFR Mutations

Por Sehgal, Kartik, Rangachari, Deepa, VanderLaan, Paul A., Kobayashi, Susumu S., Costa, Daniel B.
Publicado no Oncologist (2020)

Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?

Por Sehgal, Kartik, Varkaris, Andreas, Viray, Hollis, VanderLaan, Paul A, Rangachari, Deepa, Costa, Daniel B
Publicado no J Immunother Cancer (2020)

Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?

Por Sehgal, Kartik, Piper-Vallillo, Andrew J., Viray, Hollis, Khan, Adeel M., Rangachari, Deepa, Costa, Daniel B.
Publicado no Precis Cancer Med (2020)

Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer

Por Sehgal, Kartik, Peters, Mary Linton B., VanderLaan, Paul A., Rangachari, Deepa, Kobayashi, Susumu S., Costa, Daniel B.
Publicado no J Thorac Oncol (2018)

Association of Performance Status With Survival in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy

Por Sehgal, Kartik, Gill, Ritu R., Widick, Page, Bindal, Poorva, McDonald, Danielle C., Shea, Meghan, Rangachari, Deepa, Costa, Daniel B.
Publicado no JAMA Netw Open (2021)

Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer

Por Sehgal, Kartik, Bulumulle, Anushi, Brody, Heather, Gill, Ritu R., Macherla, Shravanti, Qilleri, Aleksandra, McDonald, Danielle C., Cherry, Cynthia R., Shea, Meghan, Huberman, Mark S., VanderLaan, Paul A., Weiss, Glen J., Walker, Paul R., Costa, Daniel B., Rangachari, Deepa
Publicado no Clin Lung Cancer (2021)

Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets

Por Sehgal, Kartik, Das, Rituparna, Zhang, Lin, Verma, Rakesh, Deng, Yanhong, Kocoglu, Mehmet, Vasquez, Juan, Koduru, Srinivas, Ren, Yan, Wang, Maria, Couto, Suzana, Breider, Mike, Hansel, Donna, Seropian, Stuart, Cooper, Dennis, Thakurta, Anjan, Yao, Xiaopan, Dhodapkar, Kavita M., Dhodapkar, Madhav V.
Publicado no Blood (2015)

Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade

Por Sehgal, Kartik, Portell, Andrew, Ivanova, Elena V., Lizotte, Patrick H., Mahadevan, Navin R., Greene, Jonathan R., Vajdi, Amir, Gurjao, Carino, Teceno, Tyler, Taus, Luke J., Thai, Tran C., Kitajima, Shunsuke, Liu, Derek, Tani, Tetsuo, Noureddine, Moataz, Lau, Christie J., Kirschmeier, Paul T., Liu, David, Giannakis, Marios, Jenkins, Russell W., Gokhale, Prafulla C., Goldoni, Silvia, Pinzon-Ortiz, Maria, Hastings, William D., Hammerman, Peter S., Miret, Juan J., Paweletz, Cloud P., Barbie, David A.
Publicado no J Clin Invest (2021)

Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research

Por Bikdeli, Behnood, Madhavan, Mahesh V., Gupta, Aakriti, Jimenez, David, Burton, John R., Der Nigoghossian, Caroline, Chuich, Taylor, Nouri, Shayan Nabavi, Dreyfus, Isaac, Driggin, Elissa, Sethi, Sanjum, Sehgal, Kartik, Chatterjee, Saurav, Ageno, Walter, Madjid, Mohammad, Guo, Yutao, Tang, Liang V., Hu, Yu, Bertoletti, Laurent, Giri, Jay, Cushman, Mary, Quéré, Isabelle, Dimakakos, Evangelos P., Gibson, C. Michael, Lippi, Giuseppe, Favaloro, Emmanuel J., Fareed, Jawed, Tafur, Alfonso J., Francese, Dominic P., Batra, Jaya, Falanga, Anna, Clerkin, Kevin J., Uriel, Nir, Kirtane, Ajay, McLintock, Claire, Hunt, Beverley J., Spyropoulos, Alex C., Barnes, Geoffrey D., Eikelboom, John W., Weinberg, Ido, Schulman, Sam, Carrier, Marc, Piazza, Gregory, Beckman, Joshua A., Leon, Martin B., Stone, Gregg W., Rosenkranz, Stephan, Goldhaber, Samuel Z., Parikh, Sahil A., Monreal, Manuel, Krumholz, Harlan M., Konstantinides, Stavros V., Weitz, Jeffrey I., Lip, Gregory Y. H.
Publicado no Thromb Haemost (2020)